Volume 15, Issue 1, Pages 137-144 (January 2018) Induced pluripotent stem cell technology and inherited arrhythmia syndromes Samantha Barratt Ross, BMedSci, Stuart T. Fraser, BSc, PhD, Christopher Semsarian, MBBS, PhD, MPH, FHRS Heart Rhythm Volume 15, Issue 1, Pages 137-144 (January 2018) DOI: 10.1016/j.hrthm.2017.08.013 Copyright © 2017 Heart Rhythm Society Terms and Conditions
Figure 1 Generation of iPSC-CMs from patients with inherited arrhythmia syndromes. CRISPR = clustered regularly interspaced short palindromic repeats; iPSC = induced pluripotent stem cell; iPSC-CM = induced pluripotent stem cell–derived cardiomyocyte. Heart Rhythm 2018 15, 137-144DOI: (10.1016/j.hrthm.2017.08.013) Copyright © 2017 Heart Rhythm Society Terms and Conditions
Figure 2 Assessment of cellular phenotype in induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) from patients with inherited arrhythmia syndromes. Heart Rhythm 2018 15, 137-144DOI: (10.1016/j.hrthm.2017.08.013) Copyright © 2017 Heart Rhythm Society Terms and Conditions
Figure 3 Potential future implications of induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) technology for the clinical cardiac electrophysiologist. Heart Rhythm 2018 15, 137-144DOI: (10.1016/j.hrthm.2017.08.013) Copyright © 2017 Heart Rhythm Society Terms and Conditions